Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy
Open Access
- 18 November 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 30 (3) , 499-509
Abstract
: Chronic kidney disease (CKD) is associated with abnormalities in bone quantity and quality, leading to increased fractures. Recent studies suggest abnormalities of Wnt signaling in animal models of CKD and elevated sclerostin levels in patients with CKD. The goal of this study was to evaluate the effectiveness of anti-sclerostin antibody treatment in an animal model of progressive CKD with low and high parathyroid hormone (PTH) levels. Cy/+ male rats (CKD) were treated without or with calcium in the drinking water at 25 weeks of age to stratify the animals into high PTH and low PTH groups, respectively, by 30 weeks. Animals were then treated with anti-sclerostin antibody at 100 mg/kg i.v. weekly for 5 doses, a single 20-µg/kg subcutaneous dose of zoledronic acid, or no treatment, and were then euthanized at 35 weeks. As a positive control, the efficacy of anti-sclerostin antibody treatment was also evaluated in normal littermates. The results demonstrated that the CKD animals with high PTH had lower calcium, higher phosphorus, and lower FGF23 compared to the CKD animals with low PTH. Treatment with anti-sclerostin antibody had no effect on any of the biochemistries, whereas zoledronic acid lowered dkk-1 levels. The anti-sclerostin antibody increased trabecular bone volume/total volume (BV/TV) and trabecular mineralization surface in animals with low PTH, but not in animals with high PTH. Neither anti-sclerostin antibody nor zoledronic acid improved biomechanical properties in the animals. Cortical porosity was severe in high-PTH animals and was unaffected by either treatment. In contrast, in normal animals treated with anti-sclerostin antibody, there was an improvement in bone volume, cortical geometry, and biomechanical properties. In summary, this is the first study to test the efficacy of anti-sclerostin antibody treatment on animals with advanced CKD. We found efficacy in improving bone properties only when the PTH levels were low. © 2014 American Society for Bone and Mineral ResearchKeywords
This publication has 47 references indexed in Scilit:
- WNT signaling in bone homeostasis and disease: from human mutations to treatmentsNature Medicine, 2013
- Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophyJournal of Bone and Mineral Research, 2012
- Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivoBone, 2011
- The pathophysiology of early-stage chronic kidney disease–mineral bone disorder (CKD-MBD) and response to phosphate binders in the ratJournal of Bone and Mineral Research, 2011
- Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patientsNephrology Dialysis Transplantation, 2011
- Effects of denosumab on fracture and bone mineral density by level of kidney functionJournal of Bone and Mineral Research, 2011
- Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controlsEuropean Journal of Endocrinology, 2010
- Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanismsJournal of Bone and Mineral Research, 2010
- A rat model of chronic kidney disease-mineral bone disorderKidney International, 2009
- Control of Bone Mass and Remodeling by PTH Receptor Signaling in OsteocytesPLOS ONE, 2008